小分子酪氨酸激酶抑制剂治疗非小细胞肺癌研究进展

Research on Development of Micromolecular Tyrosine Kinase Inhibitors in Treatment of Non-small Cell Lung Cancer

介绍小分子酪氨酸激酶抑制剂(埃罗替尼和吉非替尼)的作用机制,单药治疗及和化疗药联合治疗的临床试验,探讨化疗、放疗、表皮生长因子受体表达及突变、患者的临床特点等因素与小分子酪氨酸激酶抑制剂临床疗效的关系,阐述小分子酪氨酸激酶抑制剂治疗非小细胞肺癌的进展。

The clinical mechanisims of micromolecular Tyrosine kinase inhibitors （Erlotinib and Gefitinib）, single-dose therapy and current clinical trials of Chemotherapeutic agent are introduced. The relationship between some factors such as chemotherapy, radiotherapy, expressions and mutations of the epidermal growth factor receptors, as well as the patient＇s characteristics and the clinical efficacy of micromolecular Tyrosine kinase inhibitors is explored, in order to elucidated the development of micromolecular Tyrosine kinase inhibitors in treatment of non-small cell lung cancer.